Traders Selling Education Stocks Following Credit Suisse Downgrade on DeVry, ITT (DV, ESI, APOL, CECO, more)
Get Alerts ESI Hot Sheet
Price: $35.31 -0.65%
Rating Summary:
10 Buy, 11 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 11 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Most stocks in the Education sector are trading lower today as bearish notes from Credit Suisse on ITT (NYSE: ESI) and DeVry (NYSE: DV) may be striking a chord with investors in the group.
Credit Suisse downgraded shares of ITT and DeVry from Outperform to Neutral, saying that a regulatory draft on gainful employment (which the firm previously cited as the reason for a recent upgrade), probably won't be as beneficial after all. The firm now believes that related exemptions will be given to institutions with completion rates under 50% (in contrast to the company's previous note which estimated 50% exactly).
In the Education sector:
Credit Suisse downgraded shares of ITT and DeVry from Outperform to Neutral, saying that a regulatory draft on gainful employment (which the firm previously cited as the reason for a recent upgrade), probably won't be as beneficial after all. The firm now believes that related exemptions will be given to institutions with completion rates under 50% (in contrast to the company's previous note which estimated 50% exactly).
In the Education sector:
- DeVry - down 7% to $64.48
- ITT - down 2% to $109.59
- Apollo Group (Nasdaq: APOL) - down 1.6% to $62.49
- Strayer Education (Nasdaq: STRA) - down 1% to $250.45
- Career Education (Nasdaq: CECO) - down 1.5% To $33.59
- Corinthian Colleges (Nasdaq: COCO) - down 3% $17.32
- American Public Education (Nasdaq: APEI) - down 2.4% To $45.07
- Grand Canyon Education (Nasdaq: LOPE) - down 0.5% to $25.98
You May Also Be Interested In
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
Create E-mail Alert Related Categories
Downgrades, Insiders' Blog, Trader TalkRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share